1182 related articles for article (PubMed ID: 25893819)
1. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
2. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance.
Han N; Zhao Q; Wan L; Wang Y; Gao Y; Wang P; Wang Z; Zhang J; Jiang T; Wang S
ACS Appl Mater Interfaces; 2015 Feb; 7(5):3342-51. PubMed ID: 25584634
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
Yu M; Jambhrunkar S; Thorn P; Chen J; Gu W; Yu C
Nanoscale; 2013 Jan; 5(1):178-83. PubMed ID: 23076766
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-responsive cell-penetrating peptide conjugated mesoporous silica quantum dot nanocarriers for controlled release of nucleus-targeted drug molecules and real-time intracellular fluorescence imaging of tumor cells.
Li J; Liu F; Shao Q; Min Y; Costa M; Yeow EK; Xing B
Adv Healthc Mater; 2014 Aug; 3(8):1230-9. PubMed ID: 24550203
[TBL] [Abstract][Full Text] [Related]
5. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
6. Defect-related luminescent mesoporous silica nanoparticles employed for novel detectable nanocarrier.
Ge K; Zhang C; Jia G; Ren H; Wang J; Tan A; Liang XJ; Zang A; Zhang J
ACS Appl Mater Interfaces; 2015 May; 7(20):10905-14. PubMed ID: 25943277
[TBL] [Abstract][Full Text] [Related]
7. Dendrimerlike mesoporous silica nanoparticles as pH-responsive nanocontainers for targeted drug delivery and bioimaging.
Dai L; Zhang Q; Li J; Shen X; Mu C; Cai K
ACS Appl Mater Interfaces; 2015 Apr; 7(13):7357-72. PubMed ID: 25765172
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
9. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
Zhao Q; Liu J; Zhu W; Sun C; Di D; Zhang Y; Wang P; Wang Z; Wang S
Acta Biomater; 2015 Sep; 23():147-156. PubMed ID: 25985912
[TBL] [Abstract][Full Text] [Related]
10. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
11. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
[TBL] [Abstract][Full Text] [Related]
12. Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced chemotherapeutic functionality.
Huang P; Chen Y; Lin H; Yu L; Zhang L; Wang L; Zhu Y; Shi J
Biomaterials; 2017 May; 125():23-37. PubMed ID: 28226244
[TBL] [Abstract][Full Text] [Related]
13. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
Xiao X; Liu Y; Guo M; Fei W; Zheng H; Zhang R; Zhang Y; Wei Y; Zheng G; Li F
J Biomater Appl; 2016 Jul; 31(1):23-35. PubMed ID: 27059495
[TBL] [Abstract][Full Text] [Related]
14. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
15. A multifunctional biphasic suspension of mesoporous silica encapsulated with YVO4:Eu3+ and Fe3O4 nanoparticles: synergistic effect towards cancer therapy and imaging.
Shanta Singh N; Kulkarni H; Pradhan L; Bahadur D
Nanotechnology; 2013 Feb; 24(6):065101. PubMed ID: 23324398
[TBL] [Abstract][Full Text] [Related]
16. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
18. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
19. pH-sensitive poly(glutamic acid) grafted mesoporous silica nanoparticles for drug delivery.
Zheng J; Tian X; Sun Y; Lu D; Yang W
Int J Pharm; 2013 Jun; 450(1-2):296-303. PubMed ID: 23598077
[TBL] [Abstract][Full Text] [Related]
20. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
